# Polypill Versus Metformin in New Onset Type 2 Diabetes

> **NCT05833958** · PHASE2 · WITHDRAWN · sponsor: **George Medicines PTY Limited**

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin
- **DRUG:** Metformin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT05833958
- **Lead sponsor:** George Medicines PTY Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor has determined that this study will be postponed due to changing business priorities.
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05833958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05833958, "Polypill Versus Metformin in New Onset Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05833958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*